



O'ZBEKISTON HARBIY

2025-YIL 1-SON

Т
И
Б
И
Й
И
Й
О
Т
И



«O‘zbekiston Harbiy Tibbiyoti» ilmiy-amaliy jurnali Ўзбекистон Республикаси Олий таълим, Фан ва инновациялар вазирлиги ҳузуридаги Олий аттестация комиссиясининг 2023 йил 29 августдаги № 01-07/1410/33 сонли маълумотномасига асосан, тиббиёт фанлари буйича диссертациялар асосий илмий натижаларини чоп этиш тавсия этилган миллий илмий нашрлар рўйхатига киритилган.

Муассис:
ЎЗБЕКИСТОН РЕСПУБЛИКАСИ
ҚУРОЛЛИ КУЧЛАРИ ҲАРБИЙ
ТИББИЁТ АКАДЕМИЯСИ

Бош муҳаррир:
т/х полковниги
ФОЗИЛОВ Носиржон Хошимович.

Бош муҳаррир ўринбосари: PhD, т/х
полковниги АБДУЛАХАТОВ
Баходир Шарифжонович.

Масъул котиб:
PhD. ПЎЛАТОВА З.А.

Ўзбекистон ҳарбий тиббиёти илмий-
амалий жurnали Ўзбекистон
Республикаси Президенти
Администрацияси ҳузуридаги Ахборот
ва оммавий коммуникациялар
агентлигида 2022 йил 5 августдаги
1691-сонли гувоҳнома билан рўйхатга
олинган.

Тахририят манзили:
Тошкент шаҳри,
Зиёлилар кўчаси, 4-уй
Телефонлар: (71) 262-42-41

Тахрир хайъати:
Т.ф.д, проф. Мухамедова М.Г.
Т.ф.д., проф. Миррахимова С.Ш.
Т.ф.д., проф. Эшбеков М.Э.
Т.ф.д., проф. Ибрагимов А.Ю.
Т.ф.д., проф. Каюмов У.К.
Т.ф.д., доц. Нуралиева Д.М.
Т.ф.д., доц. Хидоятова М.Р.
Т.ф.д., доц. Расулова З.Д.
Т.ф.д., доц. Раимкулова Н.Р.
Т.ф.д., Бозорова С.А.
Т.ф.н., доц. Рахимов А.Ф.
Т.ф.н., доц. Атамуродов Ш.И.
Т.ф.н., доц. Джаббаров А.М.
PhD., доц. Файзиева Д.Б.
PhD., доц. Махмудова Н.Р.
PhD., доц. Буранкулова Н.М.
PhD., Расулов У.А.
PhD., Рустамов А.А.
PhD., Пўлатова З.А.
Т.ф.н., Мирзаев Д.А.
Т.ф.н., Ибрагимова Н.Х.
Т.ф.н., Нагаева Г.А.
Т.ф.н., Ачилов Ш.Ж.
Т.ф.н., Муродов Б.Х.
Т.ф.н., Гаджибаев Х.П.
Доц. Нуруллаев А.Ж.
Катта ўқитувчи Халимов Б.Х.
Катта ўқитувчи Мусаева Г.И.
Дизайнер:
Райхона ОЧИЛОВА.

Тахририятга юборилган мақола ва
қўлёзмаларда берилган
маълумотларнинг ҳаққонийлиги ва
ишончлилиги учун
тўлиқ жавобгарликни муаллифлар
ўз зиммасига олади.

Журнал 18.03.2025 йилда босмахонага
топширилди.

Қоғоз бичими 60x84 1/8.
Офсет усулида босилди.
Шартли 6,75 босма табок.
“Ўзбекистон Республикаси Ҳарбий тиббиёт
академияси”нинг босмахонасида чоп
этилди

1-SHO‘BA

**QUROLLI KUCHLAR TIBBIY
TA‘MINOTINI TASHKIL ETISH**

VITAMIN D EFFICIENCY FOR PREVENTION OF PREGNANCY COMPLICATIONS

ORTIQBOYEV J.O., VALIEV A.A., USMANOV D.A., AKRAMOV B.B.

Tashkent pediatric medical institute

When studying the level of vitamin D in the risk group for pre-eclampsia development pregnant women, reliably low rates were found in relation to pregnant women with physiological course of pregnancy without complications. Dependence of preeclampsia development in at-risk pregnant women on prophylactic vitamin D intake have been studied too. We have hypothesized that pregnant women having taken vitamin D have a more favorable course of pregnancy, which in turn affected the state of newborns. Therefore we have found that hypoxia of the fetus was observed 2 times less in the group of pregnant women who were taking vitamin D since 20 weeks than women who were not taking vitamin D.

Keywords: *vitamin D deficiency, pregnancy complications, pre-eclampsia.*

At present, vitamin D deficiency is considered to be a global health problem affecting a wide range of acute and chronic diseases [1, 2].

Over the past ten years, the physiological role of 25 (OH) 2D₃ has been widely studied, but data on its role in human reproduction are limited. Since vitamin D receptors have been found in reproductive tissues, including the ovaries, uterus, placenta, testicles and pituitary gland, vitamin D association with many reproductive health outcomes is requested [5, 6]. Vitamin D induces more than 3000 genes, many of which play a role in fetal development. 26 of them have a wide range of proven biological actions, including inhibition of cell proliferation and induction of final differentiation, inhibition of angiogenesis and renin production, stimulation of insulin production and production of macrophages, apoptosis induction [3, 8].

Hypertension during pregnancy and especially preeclampsia (PE) are the most studied pregnancy complications. PE syndrome is defined as the occurrence of hypertension and proteinuria after 20 weeks of pregnancy, and with a prevalence of 3-5% of all pregnancies worldwide, it is the leading cause of maternal mortality and perinatal morbidity and mortality [4, 7].

Purpose of the study: to evaluate the role of vitamin D during gestation in pregnant women at risk for pregnancy complications.

Materials and methods. The study enrolled 90 pregnant women with 18-22 weeks gestation period. The age gradation was from 19 to 40 years, the average age was 27.9±1.5 years.

Based on cohort observation we identified a risk group for PE development consisting of 60 pregnant women.

Vitamin D was determined in all cases. Vitamin D was determined by ELISA method on Elecsys-2010 (Switzerland). M.Hollick (2005) criteria were used to evaluate serum vitamin D status. Vitamin D level is considered to be sufficient at 25(OH)D level in serum over 30 ng/ml. Vitamin D deficiency means a decrease in serum concentration of 25(OH)D below 20 ng/ml (50 nmol/l); vitamin D deficiency is the concentration of 25(OH)D in serum preserved in the range of 21-29 nanograms/ml.

All pregnant women were prescribed calcium 1.5 g and vitamin D in a dose of 1500 units. During observation 30 pregnant women did not take vitamin D (comparison group), and 30 followed the prescription of a gynecologist (main group); 30 patients with physiological course of pregnancy were included in the control group.

Vitamin D level was administered again at admission for childbirth.

Statistical processing of the study results was performed using Statistica for Windows packages (version 6.1) using

parametric and non-parametric statistics (Student, Mann - Whitney criteria).

Research results. Based on our studies, we found that in PE risk pregnant women, vitamin D was significantly decreased with respect to the control group (Table 1).

Vitamin D rates at 20 pregnancy weeks pregnant control group and PE risk group

Groups	Vitamin D level	Data reliability, P<
Control group, n = 30	19,82±1,5	0,05
Main group, n = 30	12,76±1,1	
Comparison group, n = 30	13,21±1,2	

Table1

There is a more favorable course of pregnancy in the main group of pregnant women. With further observation, moderate PE in this group of pregnant women developed in 6.7% (2 pregnant women) of cases, while severe PE was not recorded. In

the comparison group in 16.7% of cases the development of PE was noted, which is 2.5 times higher with respect to the main group (P<0.05), of which severe PE was registered in 3.3% of cases (1 pregnant) and moderate PE in 13.3% (4 pregnant) (Fig. 1).




Fig. 1. Percentage of PE development among the surveyed pregnant women, depending on the use of vitamin D

All pregnant women were given birth at terms from 37 to 41 weeks, all were retested. The pregnant women of the main group had vitamin D level of 21,1±1,7 ng/ml (p<0,01) at

admission to obstetrical department, while in the comparison group its level was 1,7 times lower (Table 2)

Vitamin D rate at the period of labor in both study groups

Groups	Initial data	Pregnant without PE	Pregnant with PE	P<, to initial data	P<, к CG
Main group, n=30	12,76±1,1	21,1±1,7	18,52±1,7	0,05	-
Comparison group, n=30	13,21±1,2	12,32±1,2	11,2±1,1	-	0,01
Control group, n=30	19,82±1,5				

Table2

When analyzing the outcomes of labor, we found that 23 women (75.9%) ($p < 0.05$) of the main group had a physiological course of labor. We revealed a prolonged course of labor due to weakness of labor forces in 4 (13.2%), hypoxia of fetus in labor process in 2 (6.6%).

The following complications occurred during childbirth: premature abruption of normally located placenta in 1 (3.3%), persistent weakness of labor forces in 1 (3.3%), threatening fetal asphyxia 2 (6.6%).

In the postpartum period, hypotonic bleeding was recorded - in 3 (9.9%), chorioamnionitis and endometritis in 2 (6.6%) ($p < 0.05$).

3 patients (9.9%) had labor surgically in the planned order, 4 (13.2%) - in the emergency order, according to the indications in 1 (3.3%), 2 (5.8%) had premature abruption of the normally located placenta, 1 (3.3%) had persistent weakness of labor forces, threatening fetal asphyxia in 2 (6.6%).

When assessing the condition of newborn children of patients who took vitamin D from 20 weeks of pregnancy, it was found that 25 children (82.5%) were born in the normal condition ($p < 0.01$). Cerebral ischemia of the 1st degree was observed in 4 (13.2%) ($p < 0.01$); cerebral ischemia of the 2nd degree in 1 (3.3%); cerebral ischemia of the 3rd degree was not observed. Fetal growth delay syndrome of the 1st degree was observed in 5 (16.5%); fetal growth delay syndrome of the 2nd degree was not observed. Hyperhigh excitability syndrome was found in 2 (6.6%), intraventricular hemorrhage (IVH) - in 2 (6.6%), kefalohematoma - in 1 (3.3%), hyperbilirubinemia - in 4 (13.2%), intrauterine infection (IUI) - in 3 (9.9%).

In PE risk patients who did not take vitamin D, 19 children (62.7%) ($p < 0.01$) were born in satisfactory condition, 6 (19.8%) ($p < 0.01$) were born with the 1st degree cerebral ischemia, 3 (9.9%) - had 2nd degree cerebral ischemia and 1 (3.3%) - had the 3rd degree cerebral ischemia. Fetal growth delay syndrome of the 1st degree was observed in 10 (33%); fetal growth delay syndrome of the 2nd degree was observed in 1 (3.3%). Hyperexcitability syndrome was found in 5 (16.5%), IVH - in 3 (9.9%), kefalohematoma - in 4

(13.2%), hyperbilirubinemia - in 7 (23.1%), congenital infections - in 8 (26.4%).

Comparative analysis of the state of newborns revealed that fetal hypoxia was twice as rare as in the control group in patients who took vitamin D from 20 weeks.

Conclusion: Thus, it can be proved that vitamin D deficiency is a risk factor for the development of PE, an increase in vitamin D-level confirms the presence of polyorganic failure, which is also a risk factor for obstetric complications. The increased endothelion level in the serum causes an increase in blood pressure. As experts from the World Health Organization (2010) emphasized, the maternal status of vitamin D is very important in the prevention of complications during pregnancy.

References

1. Vasilyeva E.N., Denisova T.G., Gunin A.G., Trishina E.N. Vitamin D deficiency during pregnancy and breast-feeding. Modern problems of science and education. - 2015. - №4. - pp. 45-48
2. Shikh E.V., Milotova N.M. The role of polymorphism of the VDR gene encoding the vitamin D receptor in the pathogenesis of arterial hypertension // Biomedicine. 2009;1:55-67.
3. Alpert P.T., Shaikh U. The effects of vitamin D deficiency and insufficiency on the endocrine and paracrine systems // Biological Research for Nursing. - 2007. - №9(2). - pp. 117-129.
4. Heaney R.P. Vitamin D in health and disease // Clinical Journal of the American Society of Nephrology. 2008;3(5):1535-1541.
5. Holick M.F. Medical progress: vitamin D deficiency // New England Journal of Medicine. 2007. - №357(3). - pp. 266-281.
6. Holmes V.A., Barnes M.S., Alexander H.D., McFaul P., Wallace J.M.W.. Vitamin D deficiency and insufficiency in pregnant women: A longitudinal study // British Journal of Nutrition. - 2009. - №102(6). - pp. 876-881.
7. Lewis S., Lucas R.M., Halliday J., Ponsonby A. -L. Vitamin D deficiency and pregnancy: From preconception to birth // Molecular Nutrition and Food Research. 2010;54(8):1092-1102.

ОЦЕНКА ЭФФЕКТИВНОСТИ КОМБИНАЦИИ СЕЛДИНАФИЛА И НЕБИВАЛОЛА ПРИ ЛЕЧЕНИИ ЛЕГОЧНОЙ ГИПЕРТЕНЗИИ

ХАЖИЕВ С.О.

Ургенчский филиал Ташкентской медицинской академии

Оптимизация диагностики и лечения пациентов с фибрилляцией предсердий и высокой легочной гипертензией остается серьезной проблемой для многих стран. В 2015 году ежедневная смертность среди пациентов во всем мире достигла 114. Актуальность проблемы объясняется тем, что 17.6% больных имеют плохое или неудовлетворительное самочувствие. Нарушение сердечного ритма, хроническая обструктивная болезнь легких, ожирение, избыточная масса тела (ИМТ), артериальная гипертензия (АГ) и нарушения липидного обмена, являющиеся основными компонентами этого состояния, оказывают негативное влияние на здоровье больных. Поэтому диагностика и оптимизация лечения пациентов с фибрилляцией предсердий и высокой легочной гипертензией является важной проблемой, требующая решения.

Ключевые слова: легочной гипертензии, фибрилляцией предсердий, селдинафила и небивалол.

Optimization of diagnostics and treatment of patients with atrial fibrillation and high pulmonary hypertension remains a serious problem for many countries. In 2015, daily mortality among patients worldwide reached 114. The relevance of the problem is explained by the fact that 17.6% of patients have poor or unsatisfactory health. Heart rhythm disturbances, chronic obstructive pulmonary disease, obesity, overweight (BMI), arterial hypertension (AH) and lipid metabolism disorders, which are the main components of this condition, have a negative impact on the health of patients. Therefore, diagnosis and optimization of treatment of patients with atrial fibrillation and high pulmonary hypertension is an important problem that needs to be addressed.

Бўлмачалар фибрилляцияси ва юқори ўпка гипертензияси бўлган беморларни таъхислаш ва даволашни оптималлаштириши кўплаб мамлакатлар учун асосий муаммо бўлиб қолмоқда. 2015 йилда бутун дунё бўйлаб беморларнинг кунлик ўлим даражаси 114 га етди. Муаммонинг долзарблиги беморларнинг 17,6 фоизининг соғлиги ёмон ёки қониқарсиз эканлиги билан изоҳланади. Ушбу ҳолатнинг асосий таркибий қисмлари бўлган юрак ритмининг бузилиши, сурункали обструктив ўпка касаллиги, семизлик, ортиқча вазн (ОВ), артериал гипертензия (АГ) ва липидлар алмашинувининг бузилиши беморларнинг соғлигига салбий таъсир кўрсатади. Шунинг учун бўлмачалар фибрилляцияси ва юқори ўпка гипертензияси бўлган беморларни таъхислаш ва даволашни оптималлаштириши ҳал қилиниши керак бўлган муҳим муаммодир.

Калит сўзлар: Ўпка гипертензияси, бўлмачалар фибрилляцияси, небивалол ва селдинофил.

В настоящее время проводится ряд исследований по оптимизации диагностики и лечения пациентов с фибрилляцией предсердий и высокой легочной гипертензией среди населения мира. При скрининге ЭхоКГ 4579 пациентов за рубежом симптомы легочной гипертензии (систолическое давление в легочной артерии выше 40 мм рт. ст.) выявлены в 10.5% случаев. Лишь у 4.2% из

них была легочная артериальная гипертензия.² Точных данных о распространенности этого патологического процесса в нашей стране нет. Поэтому остается много вопросов по диагностике и оптимизации лечения пациентов с фибрилляцией предсердий и высокой легочной гипертензией. Поэтому научная работа по диагностике и оптимизации лечения легочной

53.	MUMINOVA S.U., NORQOBILOVA Z.T., SADIKOVA D.SH., ADILOVA D.A., YUSUPOVA M.SH. QANDLI DIABET 2 TURI VA METABOLIK DISFUNKSIYA BILAN BOG'LIQ JIGAR YOG' KASALLIGI: PATOGENETIK BOG'LIQLIK, DIAGNOSTIKA VA KLINIK YONDASHUVLAR	273
54.	ДАМИНОВ Б.Т., МИРХАЕТОВ М.М. ОСОБЕННОСТИ ЛИПИДНОГО СОСТАВА КРОВИ У ПАЦИЕНТОВ СТАРШЕГО ВОЗРАСТА С ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА И ХРОНИЧЕСКОЙ БОЛЕЗНЬЮ ПОЧЕК	278
55.	MUXAMEDOVA M.G., ABIDOVA D.E., MULLABAYEVA G.U., ARNAPOLSKAYA D.I ARTERIAL GIPERTENSIYANI IRSIY ASPEKTLARI: GEN POLIMORFIZMLARI GIPERTANSIYA RIVOJLANISH XAVFI QANDAY ANIQLANADI	283
56.	ДАМИНОВ Б.Т., МИРХАЕТОВ М.М. КЛИНИЧЕСКИЙ СТАТУС И КАЧЕСТВО ЖИЗНИ ПАЦИЕНТОВ С ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА И ХРОНИЧЕСКОЙ ПОЧЕЧНОЙ ПАТОЛОГИЕЙ	293
57.	МУМИНОВА С.У., МУХАММАДИЕВ А.А., МУМИНОВ К.П., НИГМОНОВ Б.Б., СУЛТАНОВА Ф.Т. ҚАНДЛИ ДИАБЕТ 2 ТУР ФОНИДА СУРУНКАЛИ ОБСТРУКТИВ ЎПКА КАСАЛЛИГИНИНГ КЛИНИК-ЛАБОРАТОР ХУСУСИЯТЛАРИ	297
58.	MUXAMMADIYEVA F.R. OSHQOZON ICHAK TRAKTINING KIMYOVIY KUYISHLARIDA BUYRAKLARDAGI MORFOMETRIK O'ZGARISHLARNING QIYOSIY TAVSIFI	301
59.	ABDUVAXITOVA A.N., NAMOZOV F.N. SIYDIK KISLOTASINING YUQORI DARAJASI FONIDA ARTERIAL GIPERTENZIYA BILAN OG'RIGAN BEMORLARNI DAVOLASHGA YANGILANGAN YONDASHUV	305
60.	НАБИЕВА Д.А., МУХАММАДИЕВА С.М., ШИРАНОВА Ш.А. ЭФФЕКТИВНОСТЬ ПРИМЕНЕНИЯ КОМБИНИРОВАННОГО ПРЕПАРАТА – РЕМИЖОИТ ПРИ ОСТЕОАРТРОЗЕ	320
61.	ORTIQBOYEV J.O., VALIEV A.A., USMANOV D.A., AKRAMOV B.B. VITAMIN D EFFICIENCY FOR PREVENTION OF PREGNANCY COMPLICATIONS	327
62.	ХАЖИЕВ С.О. ОЦЕНКА ЭФФЕКТИВНОСТИ КОМБИНАЦИИ СЕЛДИНА-ФИЛА И НЕБИВАЛОЛА ПРИ ЛЕЧЕНИИ ЛЕГОЧНОЙ ГИПЕРТЕНЗИИ	330
63.	TURSUNBAEV A.K. ARTERIAL GIPERTENSIYALI BEMORLARDA KOMPLOYANT-LIKKA TA'SIR QILUVCHI OMILLAR	336
64.	ОРТИКБОЕВ Ж.О., ВАЛИЕВ А.А., УСМОНОВ Д.А., АКРАМОВ Б.Б. КЛИНИКО-ФУНКЦИОНАЛЬНЫЕ АСПЕКТЫ ТЕЧЕНИЯ БРОНХИАЛЬНОЙ АСТМЫ В ЗАВИСИМОСТИ ОТ СИСТЕМНОГО ВОСПАЛЕНИЯ И КУРЕНИЯ У ПОДРОСТКОВ	339
65.	РАСУЛОВА М.М. ВОСПАЛИТЕЛЬНЫЙ ПРОЦЕСС В СЛИЗИСТОЙ ОБОЛОЧКЕ ПОЛОСТИ РТА ПОД ВЛИЯНИЕМ ВНЕШНИХ ФАКТОРОВ СРЕДЫ	343
66.	КОДИРОВ Д. А., ХУДАЙБЕРГАНОВ А.С., ИСРАИЛОВА Г.М., РУСТАМОВ А.А. ОЧИҚ ВА ЁНИҚ (ХИМОЯЛАНГАН) УСЛУБЛАРДА ЕТИШТИРИЛГАН ҚИШЛОҚ ХЎЖАЛИК МАХСУЛОТЛАРИНИНГ РАДИАЦИЯ МЕЪЁРИГА НИСБАТАН БИОЛОГИК ҚИЙМАТЛАРИНИ БАҲОЛАШ	352